Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Beyond Meat Inc (BYND) vs Illumina, Inc. (ILMN) Price & Performance

Beyond Meat IncTrade
Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

Beyond Meat Inc vs Illumina, Inc. — how do they compare? Beyond Meat Inc trades at $0.62 (market cap $320.23M), while Illumina, Inc. trades at $191.2 (market cap $28.93B). The key difference: Illumina, Inc. is far larger — about 90.3× Beyond Meat Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.

BYNDILMN
Market Cap
$320.23M$28.93B
Sector
Consumer StaplesHealth
52-Week High
$4.28$194.33
52-Week Low
$0.52$91.00
Enterprise Value
$630.23M$30.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Beyond Meat Inc

BYND trades at $0.63, down 4.15% today, reflecting persistent bearish sentiment amid declining revenues and negative cash flow from operations. The stock shows technical weakness with moving averages signaling bearish momentum, though oversold RSI conditions suggest potential for near-term bounce. Recent earnings show mixed results with Q1 2026 beating expectations but Q4 2025 and Q3 2025 missing estimates. The company continues expansion efforts with new product launches including Beyond Steak Filet and protein beverages.

Investment outlook remains challenging with 57% analyst sell ratings and negative operating cash flow of $145M in 2025. While valuation metrics appear attractive with P/S of 0.65 and EV/EBITDA of 2.08, ongoing revenue declines and reliance on financing activities for liquidity pose significant risks. The turnaround strategy through product diversification faces execution challenges in a competitive plant-based protein market.

Illumina, Inc.

Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.

Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.

Returns comparison

Trailing returns across standard periods

About Beyond Meat Inc

Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.

Read more on BYND

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN